Proteomics International is experienced in delivering quality, accurate results that help progress your research and business.

  • Proteomics International is ISO/IEC 17025:2005 accredited.
  • Proteomics International operates in accordance with the OECD Principles of Good Laboratory Practice (GLP).
  • Proteomics International has over 16 years of experience in analysing proteins and in the method development of quantitative assays.

ISO/IEC 17025:2005 accreditation recognises Proteomics Internationals’ ability to consistently achieve technically valid results. In Australia, ISO/IEC 17025:2005 accreditation is assessed by NATA (the National Association of Testing Authorities). ISO/IEC 17025 is recognised worldwide as the main ISO standard used by testing and calibration laboratories, and is the most widely used laboratory standard for US Federal testing laboratories. ISO/IEC 17025 is used by the FDA’s testing facilities. In 2009, the company’s laboratory was the first facility in the world to receive ISO 17025 accreditation for proteomics services.

The quality of Proteomics International’s technical expertise is demonstrated by its discovery of the protein biomarkers associated with Diabetic Kidney Disease. This discovery is currently being commercialised as a diagnostic and prognostic test for Diabetic Kidney Disease – PromarkerD. Proteomics International’s discovery, and the rigour behind the research phase was sufficiently notable that  the world’s leading mass spectrometer manufacturer, AB Sciex , released a Technote using Proteomics International’s research pipeline for Diabetic Kidney Disease to illustrate Biomarker Discovery.

  • This field is for validation purposes and should be left unchanged.